288 related articles for article (PubMed ID: 19745070)
1. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.
Arons E; Suntum T; Stetler-Stevenson M; Kreitman RJ
Blood; 2009 Nov; 114(21):4687-95. PubMed ID: 19745070
[TBL] [Abstract][Full Text] [Related]
2. Molecular variant of hairy cell leukemia with poor prognosis.
Arons E; Kreitman RJ
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):99-102. PubMed ID: 21599610
[TBL] [Abstract][Full Text] [Related]
3. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
[TBL] [Abstract][Full Text] [Related]
4. Impact of telomere length on survival in classic and variant hairy cell leukemia.
Arons E; Zhou H; Edelman DC; Gomez A; Steinberg SM; Petersen D; Wang Y; Meltzer PS; Kreitman RJ
Leuk Res; 2015 Dec; 39(12):1360-6. PubMed ID: 26520623
[TBL] [Abstract][Full Text] [Related]
5. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior.
Forconi F; Sozzi E; Cencini E; Zaja F; Intermesoli T; Stelitano C; Rigacci L; Gherlinzoni F; Cantaffa R; Baraldi A; Gallamini A; Zaccaria A; Pulsoni A; Gobbi M; Tassi M; Raspadori D; Leoncini L; Rinaldi A; Sabattini E; Bertoni F; Pileri SA; Lauria F
Blood; 2009 Nov; 114(21):4696-702. PubMed ID: 19667403
[TBL] [Abstract][Full Text] [Related]
6. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
Kreitman RJ; Wilson W; Calvo KR; Arons E; Roth L; Sapolsky J; Zhou H; Raffeld M; Stetler-Stevenson M
Clin Cancer Res; 2013 Dec; 19(24):6873-81. PubMed ID: 24277451
[TBL] [Abstract][Full Text] [Related]
7. Update on the biology and treatment options for hairy cell leukemia.
Jain P; Pemmaraju N; Ravandi F
Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
[TBL] [Abstract][Full Text] [Related]
8. Hairy cell leukaemia-variant: Disease features and treatment.
Matutes E; Martínez-Trillos A; Campo E
Best Pract Res Clin Haematol; 2015 Dec; 28(4):253-63. PubMed ID: 26614904
[TBL] [Abstract][Full Text] [Related]
9. [Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant].
Wei C; Jin XX; Cai H; Wang X; Zhuang JL; Zhou DB
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):416-421. PubMed ID: 37032137
[No Abstract] [Full Text] [Related]
10. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 in patients with classic and variant hairy cell leukemia.
Kreitman RJ; Yu T; James L; Feurtado J; Eager H; Ortiz OS; Gould M; Mauter J; Zhou H; Burbelo PD; Cohen JI; Wang HW; Yuan CM; Arons E
Blood Adv; 2023 Dec; 7(23):7161-7168. PubMed ID: 37729613
[TBL] [Abstract][Full Text] [Related]
12. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
13. Evidence of canonical somatic hypermutation in hairy cell leukemia.
Arons E; Roth L; Sapolsky J; Suntum T; Stetler-Stevenson M; Kreitman RJ
Blood; 2011 May; 117(18):4844-51. PubMed ID: 21368287
[TBL] [Abstract][Full Text] [Related]
14. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.
Xi L; Arons E; Navarro W; Calvo KR; Stetler-Stevenson M; Raffeld M; Kreitman RJ
Blood; 2012 Apr; 119(14):3330-2. PubMed ID: 22210875
[TBL] [Abstract][Full Text] [Related]
15. Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.
Salem DA; Scott D; McCoy CS; Liewehr DJ; Venzon DJ; Arons E; Kreitman RJ; Stetler-Stevenson M; Yuan CM
Cytometry B Clin Cytom; 2019 Jul; 96(4):275-282. PubMed ID: 31077558
[TBL] [Abstract][Full Text] [Related]
16. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hairy cell leukemia-variant with cladribine.
Tetreault SA; Robbins BA; Saven A
Leuk Lymphoma; 1999 Oct; 35(3-4):347-54. PubMed ID: 10706459
[TBL] [Abstract][Full Text] [Related]
18. No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
King AC; Kabel CC; Pappacena JJ; Stump SE; Daley RJ
Ann Pharmacother; 2019 Sep; 53(9):922-932. PubMed ID: 30841702
[No Abstract] [Full Text] [Related]
19. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.
Ravandi F; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Koller C; Challagundla P; York S; Brandt M; Luthra R; Burger J; Thomas D; Keating M; Kantarjian H
Blood; 2011 Oct; 118(14):3818-23. PubMed ID: 21821712
[TBL] [Abstract][Full Text] [Related]
20. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment.
Maitre E; Cornet E; Troussard X
Am J Hematol; 2019 Dec; 94(12):1413-1422. PubMed ID: 31591741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
